Aldeyra Therapeutics (ALDX) told investors its dry eye drug reproxalap was showing strong, consistent results across multiple late-stage trials. Fast onset. Clinically meaningful data. But the story investors got was very different from what regulators would later say.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Investors who purchased Aldeyra Therapeutics stock during a multi-year period are now facing steep losses after the FDA rejected the company’s application for its lead drug candidate.
Aldeyra Therapeutics, is the subject of a federal securities lawsuit filed in the District of Massachusetts on March 30, 2026. The complaint alleges that between November 3, 2023 and March 16, 2026, the company repeatedly made materially false and misleading statements about the clinical trial results for its lead drug, reproxalap. According to the complaint, the alleged truth emerged on March 17, 2026, when the FDA issued a Complete Response Letter rejecting the drug application, citing inconsistent study results and a failure to demonstrate efficacy. On that date, Aldeyra’s stock allegedly fell $2.99 per share, or approximately 70.7%, closing at $1.24. Investors who purchased Aldeyra securities during the class period may have legal rights. Learn more about your eligibility here.
Aldeyra Therapeutics: Biotech Company Behind a Novel Drug Platform
Aldeyra describes itself as a biotechnology company focused on discovering innovative therapies for immune-mediated diseases. The company is incorporated in Delaware and headquartered in Lexington, Massachusetts, with shares trading on the NASDAQ under the ticker symbol ALDX.
Central to the lawsuit is reproxalap, a novel reactive aldehyde species (RASP) inhibitor that Aldeyra was investigating as a treatment for dry eye disease, among other conditions. The complaint identifies reproxalap as the company’s first-in-class product candidate for dry eye disease.
What the Lawsuit Alleges: Clinical Trial Claims Under Scrutiny
The lawsuit centers on statements Aldeyra made over multiple years about the performance of reproxalap in clinical trials. According to the complaint, the company repeatedly characterized the drug as having demonstrated broad-based, rapid-onset activity and consistent safety across multiple Phase 2 and Phase 3 trials, including claims of statistically significant and clinically relevant results occurring within minutes of dosing. The complaint alleges that these statements were materially false and misleading because the clinical trial results were, in reality, inconsistent, rendering any positive findings unreliable and not meaningful.
The core of the plaintiff’s theory is that Aldeyra publicly promoted reproxalap’s clinical track record while allegedly concealing that the trial results were inconsistent, making any positive findings unreliable and not meaningful..
Investors who followed the case or are evaluating their legal options can learn more about developments as they unfold.
What Management Said: Statements Across Four SEC Filings
The complaint cites a pattern of statements made across four separate regulatory filings. In the quarterly report filed on November 3, 2023, signed by CEO Todd C. Brady and then-CFO Bruce M. Greenberg, Aldeyra stated that reproxalap had demonstrated broad-based, rapid-onset activity and consistent safety across multiple clinical trials.
In the annual report for fiscal year 2023, filed March 7, 2024, and again signed by Brady and Greenberg, the company repeated that reproxalap had demonstrated consistent statistically significant and clinically relevant activity across a variety of symptoms and signs, occurring as early as within minutes of dosing. Those same or substantially similar statements appeared in the fiscal year 2024 annual report filed February 28, 2025, signed by Brady and incoming principal financial officer Michael Alferi, and again in the fiscal year 2025 annual report filed February 27, 2026, also signed by Brady and Alferi.
How the Alleged Truth Emerged: The FDA’s Complete Response Letter
On March 17, 2026, before the market opened, Aldeyra filed a Form 8-K disclosing receipt of a Complete Response Letter from the FDA. According to the complaint, the FDA stated that the application lacked substantial evidence from adequate and well-controlled investigations supporting the drug’s effectiveness, and that the application had failed to demonstrate efficacy in adequate and well-controlled studies in the treatment of signs and symptoms of dry eye disease. The FDA also stated that the inconsistency of study results raised serious concerns about the reliability and meaningfulness of the positive findings, and that the totality of evidence from completed clinical trials did not support the effectiveness of the product.
Following this disclosure, Aldeyra’s stock price declined approximately 70.7% on March 17, 2026, falling $2.99 per share to close at $1.24. The complaint alleges that this decline reflects the market absorbing information that had allegedly been concealed or misrepresented throughout the class period.
Why This Case May Matter to Aldeyra Shareholders
The complaint alleges that investors purchased Aldeyra shares at prices that were artificially inflated due to repeated public statements about reproxalap’s clinical performance that did not accurately reflect the reliability of the underlying data. When the FDA’s rejection letter became public, allegedly revealing that the trial results were inconsistent and that the drug had not demonstrated efficacy, the stock lost more than two-thirds of its value in a single trading session.
Shareholders who purchased ALDX stock between November 3, 2023 and March 16, 2026 may have incurred losses tied directly to this alleged disclosure event. The lawsuit is brought on behalf of all investors who acquired Aldeyra securities on the NASDAQ during that period and were allegedly damaged as a result.
Legal Claims Filed Against the Company and Individual Defendants
The complaint asserts two counts under the Securities Exchange Act of 1934. Count I alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 against all defendants, claiming that Aldeyra and its officers disseminated materially false and misleading statements and omitted material facts that investors needed to make informed decisions about the company’s drug development program. Count II alleges violations of Section 20(a) against the individual defendants, Brady, Alferi, and Greenberg, on the theory that as senior officers with control over company communications and filings, they are liable as controlling persons for the underlying securities violations.
Investors who purchased Aldeyra securities during the class period and wish to learn more about their legal rights may want to consult with a qualified securities attorney.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.